Substituted bridged urea analogs as sirtuin modulators
The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
1. A compound or pharmaceutically acceptable salt thereof, selected from
2. A compound or pharmaceutically acceptable salt according to claim 1 wherein the compound is (4S)—N5-(5-((R)-2,3-dihydroxypropoxy)pyrazin-2-yl)-N7-(2,2,2-trifluoroethyl)-3,4-dihydro-1,4-methanopyrido[2,3-b][1,4]diazepine-5,7(2H)-dicarboxamide
3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
4. The pharmaceutical composition of claim 3 further comprising an additional active agent.
5. A method for treating insulin resistance, a metabolic syndrome, metabolic dysfunctions, or complications thereof, or for increasing insulin sensitivity, comprising administering compound or pharmaceutically acceptable salt according to claim 1 to a subject in need thereof.
6. A method for treating diseases or disorders resulting from diminished SIRT1 expression or activity, which comprises administering compound or pharmaceutically acceptable salt according to claim 1 to a subject in need thereof.
7. The method according to claim 6 wherein the diseases or disorders resulting from diminished SIRT1 expression or activity are elected from aging or stress, metabolic dysfunctions, neurodegenerative diseases, cardiovascular disease, or inflammatory disease.
8. The method according to claim 6 , wherein diseases or disorders are selected from psoriasis, atopic dermatitis, acne, rosacea, warts, inflammatory bowel disease, Crohn's Disease, ulcerative colitis, osteoporosis, sepsis, arthritis, COPD, systemic lupus erythematosus, phthalmic inflammation, alopetia, treatment of wounds, ocular disorders, dry eye, keratitis and uveitis.
9. The method according to claim 8 , wherein the disease is inflammatory bowel disease, Crohn's Disease, or ulcerative colitis.
10. A method for treating insulin resistance, a metabolic syndrome, metabolic dysfunctions, or complications thereof, or for increasing insulin sensitivity, comprising administering a pharmaceutical composition according to claim 3 to a subject in need thereof.
11. A method for treating diseases or disorders resulting from diminished SIRT1 expression or activity, comprising administering a pharmaceutical composition according to claim 3 to a subject in need thereof.
12. The method according to claim 11 wherein the diseases or disorders resulting from diminished SIRT1 expression or activity are elected from aging or stress, metabolic dysfunctions, neurodegenerative diseases, cardiovascular disease, or inflammatory disease.
13. The method according to claim 11 , wherein diseases or disorders are selected from psoriasis, atopic dermatitis, acne, rosacea, warts, inflammatory bowel disease, Crohn's Disease, ulcerative colitis, osteoporosis, sepsis, arthritis, COPD, systemic lupus erythematosus, phthalmic inflammation, alopetia, treatment of wounds, ocular disorders, dry eye, keratitis and uveitis.
14. The method according to claim 13 , wherein the disease is inflammatory bowel disease, Crohn's Disease, or ulcerative colitis.